Phoenix, ARIZONA9 Active Studies

Geographic Atrophy Clinical Trials in Phoenix, ARIZONA

Find 9 actively recruiting geographic atrophy clinical trials in Phoenix, ARIZONA. Connect with local research sites and explore new treatment options.

9
Active Trials
8
Sponsors
3,996
Enrolling

Recruiting Geographic Atrophy Studies in Phoenix

RecruitingPhoenix, ARIZONANCT05633654

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatmen...

1,514 participants
Gilead Sciences
View Study Details
RecruitingPhoenix, ARIZONANCT06764875

A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

This is a Phase â…¢, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) c...

840 participants
AstraZeneca
View Study Details
RecruitingPhoenix, ARIZONANCT06291376

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease pro...

510 participants
Alexion Pharmaceuticals, Inc.
View Study Details
RecruitingPhoenix, ARIZONANCT06564142

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function....

480 participants
Alpine Immune Sciences Inc, A Subsidiary of Vertex
View Study Details
RecruitingPhoenix, ARIZONANCT05949593

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects...

429 participants
Belite Bio, Inc
View Study Details
RecruitingPhoenix, ARIZONANCT06624670

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers. This...

90 participants
Boehringer Ingelheim
View Study Details
RecruitingPhoenix, ARIZONANCT06388083

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease...

60 participants
Belite Bio, Inc
View Study Details
RecruitingPhoenix, ARIZONANCT05956626

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Phase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either ...

51 participants
Ocugen
View Study Details
RecruitingPhoenix, ARIZONANCT05831176

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

This study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participan...

22 participants
Regeneron Pharmaceuticals
View Study Details

About Geographic Atrophy Clinical Trials in Phoenix

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 9 geographic atrophy clinical trials recruiting participants in Phoenix, ARIZONA. These studies are seeking a combined 3,996 participants. Research is being sponsored by Gilead Sciences, AstraZeneca, Alexion Pharmaceuticals, Inc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Phoenix — FAQ

Are there geographic atrophy clinical trials in Phoenix?

Yes, there are 9 geographic atrophy clinical trials currently recruiting in Phoenix, ARIZONA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Phoenix?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Phoenix research site will contact you about next steps.

Are clinical trials in Phoenix free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Phoenix studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 9 active trials in Phoenix are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated March 2, 2026 from ClinicalTrials.gov